ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2013
Intracerebral propagation of Alzheimer's disease: strengthening evidence of a herpes simplex virus etiology.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Association between herpes zoster and cognitive impairment among Chinese community-dwelling elderly: a cross-sectional study.BMC public health · 2026Observational
- HSV-1 strain H129 co-opts neuronal synaptic transmission machinery for its transsynaptic spread.Nature neuroscience · 2026Article
- What would it take to prove that a chronic infection is a causal agent in Alzheimer's disease?Trends in neurosciences · 2025Review
- Intranasal delivery of engineered extracellular vesicles promotes neurofunctional recovery in traumatic brain injury.Journal of nanobiotechnology · 2025Article
- Computational design and evaluation of multiepitope vaccines against herpes simplex virus type 1.Frontiers in immunology · 2025Article
- Drug target of natural products and COVID-19: how far has science progressed?Annals of medicine and surgery (2012) · 2023Article
- Adamantanes for the treatment of neurodegenerative diseases in the presence of SARS-CoV-2.Frontiers in neuroscience · 2023Review
- Bioactivity and In Silico Studies of Isoquinoline and Related Alkaloids as Promising Antiviral Agents: An Insight.Biomolecules · 2022Review
- SARS-CoV-2 Invasion and Pathological Links to Prion Disease.Biomolecules · 2022Article
- Neuropathologic Findings in Elderly HIV-Positive Individuals.Journal of neuropathology and experimental neurology · 2022Article
- The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Intranasal drug delivery: opportunities and toxicologic challenges during drug development.Drug delivery and translational research · 2022Review
- SARS-CoV-2 Neuroinvasion, Inflammatory Neurodegeneration and Alzheimer's Disease.Frontiers in cellular neuroscience · 2022Article
- Linking Oxidative Stress and Proteinopathy in Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2021Review
- Medicinal plants: Treasure for antiviral drug discovery.Phytotherapy research : PTR · 2021Review
- Potential of Malawi's medicinal plants in Covid-19 disease management: A review.Malawi medical journal : the journal of Medical Association of Malawi · 2021Review
- A review on potential of natural products in the management of COVID-19.RSC advances · 2021Review
- The Hippocampal Vulnerability to Herpes Simplex Virus Type I Infection: Relevance to Alzheimer's Disease and Memory Impairment.Frontiers in cellular neuroscience · 2021Review
- Inflammation Spreading: Negative Spiral Linking Systemic Inflammatory Disorders and Alzheimer's Disease.Frontiers in cellular neuroscience · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundA faulty human protein, abnormally phosphorylated tau, was recently publicized to spread "like a virus" from neuron to neuron in Alzheimer's patients' brains. For several decades, we have been amassing arguments showing that herpes simplex virus type 1 (HSV-1), not p-tau, propagates this interneuronal, transsynaptic pathologic cascade.
methodsWe reiterate convincing data from our own (and other) laboratories, reviewing the first anatomic foothold neurofibrillary tangles gain in brainstem and/or entorhinal cortex; the chronic immunosurveillance cellularity of the trigeminal ganglia wherein HSV-1 awakens from latency to reactivate; the inabilities of p-tau protein's physical properties to promote it to jump synapses; the amino acid homology between human p-tau and VP22, a key target for phosphorylation by HSV serine/threonine-protein kinase UL13; and the exosomic secretion of HSV-1-infected cells' L-particles, attesting to the cell-to-cell passage of microRNAs of herpesviruses.
resultsThe now-maturing construct that reactivated HSV-1 best accounts for the intracerebral propagation of AD changes in the human brain should at last seem highly attractive. This hypothesis might even explain statins' apparent mechanism in some studies for lowering AD incidence.
conclusionProvided that funding agencies will quickly ignite a new realm of investigation, the rejuvenated enthusiasm for testing this optimistic construct holds incalculable potential for rapid, efficacious clinical application, through already available and relatively safe antiviral therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.